KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitReceivables - NetReceivables Refunds
Ratios

Takeda Pharmaceutical (TAK) Receivables Refunds (2018 - 2026)

Takeda Pharmaceutical has reported Receivables Refunds over the past 9 years, most recently at $204.3 million for Q1 2026.

  • For Q1 2026, Receivables Refunds rose 97.39% year-over-year to $204.3 million; the TTM value through Mar 2026 reached $204.3 million, up 97.39%, while the annual FY2026 figure was $212.8 million, 105.32% up from the prior year.
  • Receivables Refunds was $204.3 million for Q1 2026 at Takeda Pharmaceutical, up from $103.5 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $243.9 million in Q1 2023 and bottomed at $103.5 million in Q1 2025.
  • The 5-year median for Receivables Refunds is $204.3 million (2026), against an average of $197.5 million.
  • Year-over-year, Receivables Refunds tumbled 47.49% in 2025 and then soared 97.39% in 2026.
  • Over 5 years, Receivables Refunds stood at $238.6 million in 2022, then rose by 2.21% to $243.9 million in 2023, then dropped by 19.2% to $197.1 million in 2024, then tumbled by 47.49% to $103.5 million in 2025, then skyrocketed by 97.39% to $204.3 million in 2026.
  • The last three reported values for Receivables Refunds were $204.3 million (Q1 2026), $103.5 million (Q1 2025), and $197.1 million (Q1 2024) per Business Quant data.